ReviewFrontiers in molecular biosciences2025
Recent progress in human telomerase structure and its therapeutic targeting.
Review in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most cancer and stem cells activate telomerase to preserve critical genetic material during cell division. Telomerase is a reverse transcriptase ribonucleoprotein that adds telomeric repeats to chromosome ends, thus overcoming the end-replication problem. Shortening of telomeric repeats, or telomeres, is associated with genomic instability, cancer, and aging. Telomerase dysfunction during early development leads to telomeropathies such as dyskeratosis congenita, pulmonary fibrosis, and aplastic anaemia. Recent advancements in cryo-electron microscopy and improved strategies for purifying human telomerase have laid a strong foundation in the structural biology of telomerase, advancing our understanding of its molecular interactome. In this report, we review the latest progress in human telomerase structure and outline emerging therapeutic strategies targeting telomerase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.